Purpose To estimate the lifetime cost consequences for society and the National Health Service (NHS) of bilateral monofocal (SI40NB) or multifocal (ReSTOR or Array-SA40) intraocular lense (IOL) implantation after cataract surgery. Setting Public hospital in the Netherlands. Methods A Markov model simulated three cohorts of patients followed 69 until 100 years of age, or death. Spectacle independence rates for each IOL were adjusted to the results of a randomized clinical trial that compared monofocal and multifocal Array-SA40 IOL implants, together with a prospective cohort of patients implanted with ReSTOR. Adjustment was performed using the propensity score method in a multivariate analysis. Resource consumption was estimated from a dedicated Dutch survey. Dutch unit costs were applied to spectacles, cataract surgery, IOLs, visits to ophthalmologists, optometrists, transport, and spectacle cleaning materials. Cost discounted at 4% and undiscounted economic results were calculated. Results Spectacle independence rates were 86.0% for ReSTOR, 8.7% for monofocal IOLs, and 8.5% for Array-SA40. Patients lived without needing spectacles for 12.9 years after ReSTOR, for 1.4 years after monofocal IOLs, and 1.3 years after Array-SA40. ReSTOR patients bought 6.4 fewer pairs of spectacles than monofocal patients. Lifetime discounted cost consequences for the society were ReSTOR h3969, monofocal IOLs h4123, and Array-SA40 h5326. Corresponding costs for the NHS were h2415, h2555, and h2556, respectively. Conclusions ReSTOR IOLs provided higher levels of spectacle independence than monofocal SI40NB or multifocal Array-SA40 IOLs resulting in savings, compared to a monofocal, over the period modelled of h315 for society and h140 for the NHS.
Introduction
Typical senile cataract progresses slowly and if untreated can cause vision loss. It is the leading cause of blindness in the world affecting an estimated 20.5 million (17.2%) Americans over 40 years of age. [1] [2] [3] However, most populations in the Western world have access to cataract surgery, for example, 6.1 million American citizens (5.1%) have pseudophakia/aphakia. It is predicted that Americans with cataract will increase to 30.1 million by 2020 of which 9.5 million are expected to undergo pseudophakia/ aphakia. 1 Cataract surgery is the most frequently performed surgical intervention in the Netherlands and the number of cataract surgeries has increased from 80 000 procedures per year in 1998 to 160 000 procedures per year in 2006. 4 More than 80% of patients regain good bestcorrected visual acuity (VA 48/10 Snellen equivalent) after cataract surgery, depending on other ocular pathologies and follow-up duration. [5] [6] [7] [8] [9] Multifocal intraocular lenses (IOLs), implanted during presbyopia or cataract surgery, were developed to free patients from spectacles, by applying the principle of simultaneous vision. 10 Improvements in multifocal IOL technology led to better VA over a longer range of distances and a degree of spectacle independence. 11 Early designs of multifocal IOLs were associated with reduced contrast sensitivity, and complaints of halos and glare. Today, in routine practice, multifocal IOLs enable functional near and distance vision and an acceptable level of patient satisfaction. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Recently, a new apodized multifocal IOL (Acrysof ReSTOR) was marketed. It provides good functional near, intermediate, and distance vision such that 80% of patients never wear spectacles again.
According to Vitale et al 25 more than 110 million Americans can achieve normal vision after refractive correction. However, spectacle prescriptions incur costs for both patients and health insurance providers. The direct annual US cost of simply correcting impaired distance vision was at least $3.8 billion, of which $780 million related to persons aged 465 years. To the best of our knowledge, no data have been published on the costs associated with wearing spectacles after cataract surgery, apart from a survey by Cuq et al, 26 covering France, Germany, Italy, and Spain, which found costs varying from h230 (Spain) to h579 (France). Cost savings have been estimated for 'laser-assisted in situ keratomileusis', 27 but so far no lifelong data have been published for multifocal IOLs.
The aim of the present economic analysis was to compare the lifetime costs and consequences of cataract surgery with implantation of a multifocal ReSTOR IOL, a multifocal Array-SA40 IOL, and a monofocal PhacoFlex-SI40 NB IOL.
Materials and methods

Effectiveness sources
Data from a clinical trial 28 that compared a monofocal IOL (PhacoFlex-SI40 NB; AMO, Irvine, CA, USA) to a multifocal IOL (Array-SA40; AMO). This randomized controlled trial included cataract patients with no ocular comorbidity. Near VA and distance VA were measured preoperatively, 3 months after first-eye surgery, and 3 months after second-eye surgery. Spectacle dependence, vision-related functioning, and patient satisfaction were collected as well. Multifocal IOLs showed significantly better uncorrected near VA than monofocal IOLs. Patients with multifocal IOLs were more likely to 'never' or 'only now and then' wear spectacles for near and distance than patients with monofocal IOLs. Satisfaction related to preoperative expectations was similar in the monofocal and multifocal groups.
These data were contrasted with data from a patient cohort implanted with the ReSTOR SN60D3 (Alcon Laboratories, Fort Worth, TX, USA) in a trial with similar follow-up and data collection. All patients had bilateral senile cataract, corneal astigmatism p1.5D, and were followed-up for at least 6 months. VA and rates of spectacle independence in the three IOL groups were compared indirectly, after adjusting for potential confounding variables. Adjustment was performed by (1) linear regression and (2) the propensity score. 29, 30 Potential confounding variables were demographic characteristics, preoperative near and distance vision, post-surgical follow-up time, and a neuroticism score. Neuroticism was expressed by the Neuroticism scale of the Eysenck Personality QuestionnaireFRevised Short Scale, 31 and ranged from 0 ('not at all neurotic') to 12 ('highly neurotic'). In addition, patients self-rated their uncorrected VA according to one of five categories, that is, 'Excellent'/'Good'/'Satisfactory'/'Fair'/'Poor'.
Resource and unit cost
A separate, dedicated, survey was performed to estimate the costs and resources associated with spectacle use after cataract surgery. The survey was conducted at 10 Dutch ophthalmologic centres. The selection of centres followed local advice on representative spectacle prescriptions. Centres were not selected at random. Each site was required to include 10-12 patients meeting the following criteria:
Age X45 years at the time of cataract surgery Patients with senile cataract surgery in both eyes Patients needing spectacles after cataract surgery Patients capable of reading and understanding Dutch, knowing the objectives of the enquiry, and agreeing to participate in the survey (oral consent) Collected information concerned the type and cost of spectacles purchased, distances to ophthalmologists and optic centres, and resources consumed in purchasing and caring for spectacles. Information was also gathered on the number of visits to ophthalmologists and optic centres, spectacle replacement frequencies, spectacle maintenance frequencies (at visits), the mean distance to care providers, and time spent (travel and spectacle cleaning) on vision care.
Two economic perspectives were considered, society and National Health Service (NHS). Results were expressed in Euros (2007) and a 4% discount rate was applied.
National tariffs and survey estimates were used to cost consumed resources. Cataract surgery costs were estimated from the national DRG list. 32 For the societal perspective, spectacle costs were calculated from Dutch optic centre statistics, 33 transportation costs from market prices, and costs for 'time spent' from average Dutch wages.
Markov model
An existing Markov model ( Figure 1 ) was used to estimate the lifetime cost consequences for Dutch society and the NHS after bilateral ReSTOR implants when compared to the monofocal IOL and Array-SA40 implants. 27, 34, 35 TreeAge software version 4.0 (Williamstown, MA, USA) was used to simulate cohorts of patients. Each cohort with a specified IOL implanted bilaterally during cataract surgery at age 69 years was followed until death or age 100 years. This age is representative of patients having cataract surgery in the EU countries. After surgery patients were assigned to one of two possible health states, spectacles either 'not needed' or spectacles 'needed and purchased'. The adjusted frequency rate of 'not needed' spectacles was derived from a pooled analysis of patients in the Nijkamp clinical trial 28 and the ReSTOR cohort. During all subsequent cycles, patients could enter one of three visual states ('spectacles not needed', 'spectacles needed and purchased', or 'spectacles needed and not purchased') or the terminal state (death). The duration of a cycle was 1 month and patients were eliminated at death or upon reaching 100 years. National mortality statistics were used for life expectancy. 36 Sensitivity analyses were performed on the discount rates (0, 4%) and costs of spectacles and time horizon (10, 20 , and 30 years).
Results
Effectiveness comparison of three IOLs
Data from 220 patients pooled from the Nijkamp clinical trial 28 and a prospective ReSTOR cohort were analysed. Patients were distributed as n ¼ 83 (37.7%) in the ReSTOR group, n ¼ 69 (31.4%) in the monofocal group, and n ¼ 68 (30.9%) in the Array-SA40 group. Table 1 presents demographic characteristics of all three groups at baseline.
The overall mean age was 68.8(±12.4) years, but patients with ReSTOR implants were younger (62.3 years) than those in the other groups, that is monofocal IOL patients (72.3 years) and Array-SA40 patients (73.0 years) (Po0.001). There was no gender difference between patients in the three IOL groups of which 40.0% were men. Also, the neuroticism score was significantly lower (P ¼ 0.004) in patients with ReSTOR implants (mean 2.5) as compared to patients with monofocal IOL implants (mean 3.8) or Array-SA40 (mean 4.1).
Before surgery, mean uncorrected distance VA (LogMAR units) for the best eye was 0.48( ± 0.3) and mean corrected distance VA was 0.23( ± 0.24). Astigmatism (defined as cylinder pÀ1) affected 48.6% of patients and was bilateral in 15.0%. Patients who subsequently received multifocal IOLs had the worst uncorrected near VA. Distance vision without spectacles was self-rated as 'Poor' by more than 45% of patients, and near vision without spectacles was rated as 'Poor' by 40%. Only 6.1% of patients did not use spectacles, whereas 66.7% were dependant on spectacles for both near and distance vision.
Six months after surgery (Table 2 ) distance and near VA improved for all patients. Post-operative uncorrected distance VA did not differ significantly between the three implant groups. By contrast, notable differences of uncorrected near VA were observed between the IOL groups. Patients implanted with ReSTOR had a mean uncorrected near VA of o0 LogMAR that was significantly (Po0.001) better than the monofocal IOL and Array-SA40 (mean of 0.18 and 0.08 LogMAR respectively). Self-rated near vision without spectacles was better with ReSTOR than with the other IOLs, and was rated as 'Excellent' or 'Good' by 83.6% of patients implanted with ReSTOR, compared to 26.2% for patients with the monofocal IOL and 32.4% with Array-SA40. Moreover, 86.4% of patients did not wear spectacles after ReSTOR implants, in contrast to only 8.5% of patients with monofocal IOLs and 8.1% with Array-SA40. Patients who continued to wear spectacles after ReSTOR implants did so for either distance or near vision only, but not for both. Also, spectacle types differed significantly (Po0.001) according to the type of IOL implanted, such that patients with ReSTOR never needed bifocal or varifocal spectacles. Table 3 reports results after adjustment for confounding factors, which did not change the results dramatically. After adjustment, uncorrected near VA was À0.21 LogMAR better for patients with ReSTOR, compared to monofocal implants (Po0.001). Also, patients with ReSTOR had a greater probability of freedom from spectacles than patients with monofocal IOLs (RR ¼ 10.2). The difference persisted and increased after adjustment for the propensity score (RR ¼ 11.1). A similar difference in favour of ReSTOR was observed with the Array-SA40 comparison.
Cost of refraction in the Netherlands
Resources consumed by spectacle dependence are presented in Table 4 . Spectacles were replaced approximately every 3 years (40 months) and a refraction visit (optometrist in nearly 50% of cases) was required for each pair of spectacles purchased. The mean time dedicated to IOL surgery was 16 h (2 workdays) per patient and a mean of 1.56 relatives attended each patient.
According to Table 2 , spectacle types depended on the IOL implanted, for example patients with ReSTOR IOLs mostly bought distance spectacles costing h227. 
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Spectacles with the other IOLs were mainly for reading (h108), but included more bifocal (h355.5) or varifocal lenses (h484), the most expensive. The average cost of spectacles after cataract surgery was h193.5 for ReSTOR, h211.8 for Array-SA40, and h287.5 for monofocal IOLs. The cost of implanting an IOL was h137, irrespective of the type. However, a patient co-payment of h800 was added to the cost of cataract surgery when a multifocal IOL was implanted, which was not reimbursed by the NHS. Spectacle cleaning costs were estimated at h7 and were not reimbursed by the NHS. Also, the Dutch NHS only partially reimbursed ophthalmologist visits; optometrist visits and spectacle costs were not reimbursed.
Costs per kilometre of car travel were estimated at h0.16 and h2.80 for parking (Table 5) . Taxi costs per kilometre were estimated at h1.75 and a h2.80 hire fee. Subway/bus costs were estimated at h0.16 per kilometre, depending on the distance travelled, type of ticket, etc). The average transportation cost per kilometre to visit ophthalmologists was h3.22 and to optic centres was h1.71.
Comparative cost analysis
The average life expectancy of our population aged 69 was 14.9 years. Patients implanted with ReSTOR gained an average of 11.5 years freedom from spectacles (Table 6 ). Compared to patients with monofocal IOLs or Array-SA40, patients with ReSTOR saved average lifetime costs of 3.7-6.4 spectacle pairs, 7.4-12.6 cleaning packs, 3.6-6.3 optical correction visits, 227.2-392.8 km of travel to optic centres and ophthalmologists, and 3.7-6.5 h spent on VA care.
From the societal perspective, at the end of our 30-year model (costs discounted at 4%), patients implanted with ReSTOR spent less on spectacles and cleaning materials, visits for refraction, and transport, than patients with monofocal IOLs or Array-SA40 (Table 7) . ReSTOR implants resulted in overall savings of h315.4 compared to monofocal IOLs. By contrast, Array-SA40 costs h1203.9 more than monofocal IOLs. Results with a 0% discount rate reinforced the previous differences. 
Eye
The NHS perspective yielded similar results ( Table 8 ), except that differences between the IOLs were smaller because refraction costs were largely borne by patients.
Conclusion
The present economic analysis estimated cost consequences in the Netherlands following cataract surgery with implantation of a ReSTOR multifocal, an Array-SA40 multifocal, or a monofocal PhacoFlex-SI40 NB IOL, using a Markov model with cataract surgery at age 69 and patients followed until death, or age 100 years. The economic perspectives were those of society and the Dutch NHS. Monofocal IOLs represent today's care standard and are covered by the Dutch NHS. Multifocal IOLs have been introduced more recently and are only partially covered by the Dutch NHS. The current study uses an economic model to determine whether higher costs of a multifocal IOL are compensated by subsequent lower costs of spectacles due to higher levels of spectacle independence. ReSTOR IOLs provided higher levels of spectacle independence than did monofocal or Array-SA40 IOLs resulting in savings over the period modelled of h315 for society and h140 for the NHS. Our study wholly concerned the Netherlands, using Dutch mortality rates and cataract prevalence data, and patient data derived from a previously published clinical trial. The consequent combination of national survey and clinical trial data provides a guarantee of good internal and external validity, as recommended by most health economics guidelines. 37 Uncorrected distance VA was similar between the three IOLs; uncorrected near VA was better with multifocal IOLs than monofocal IOLs; and ReSTOR was the superior multifocal IOL, compared to Array-SA40. These results were complemented by the higher spectacle independence rate with ReSTOR implants. Although ReSTOR was not allocated randomly, the results adjusted by two methods were consistent with unadjusted findings. It should be noted that the spectacle types chosen contributed significantly to the economic outcome, as ReSTOR obviated the need for bifocal and varifocal lenses, that is, the most expensive alternatives.
With ReSTOR implants, fewer than 15% of patients required spectacles after cataract surgery, making this lens consistently more economically advantageous than monofocal or Array-SA40 IOLs, when calculated with a 30-year time horizon and 4% discount rate.
At an incremental cost of h800 paid by patients for multifocal IOL implants, ReSTOR provided savings of h315 for society and h140 for the NHS. That the discount rate significantly modified our results is not surprising in view of the long follow-up period (up to 30 years) built into our model. Two factors lay behind the economic benefit of ReSTOR, that is, time and spectacle independence. The difference between ReSTOR and Array-SA40 costs showed that when the spectacle independence rate difference is insufficient, multifocal implants will not produce savings compared to monofocal IOLs. The same point was made by Lafuma and Berdeaux. 34, 35 We adopted a very conservative approach when choosing our assumptions. The non-financial benefits of freedom from spectacles after cataract surgery were not considered by the present analysis, but Cuq et al 26 found that approximately 50% of patients were willing to pay for this freedom. Previously, some ReSTOR patients reported broader vision (unrestricted by a spectacle frame), feelings of well-being, freedom, youthfulness, improved socialization, and so on. 38 In our economic analysis, we have not taken into account the additional time required to prepare a patient for a multifocal implantation. This approach is certainly acceptable according to the NHS economic perspective because these resources are already included, at least theoretically, in the DRG value. However, according to a societal perspective, it would be worth estimating them and fix how much a DRG should be modified to account for the additional work. More broadly, time and motion analyses should be performed every time a new technology is available for cataract surgery to question the validity of the DRG value.
Also we have not accounted for IOL explantation because none of them were observed in this cohort. A 2-4% explantation incidence rate would lead to a 21-42h additional cost.
Our analysis is subject to the following limitations: (1) no model can replace real longitudinal data, but the feasibility and economics of such a survey may be questioned; (2) we hypothesized that the prevalence rate of spectacle independence remains constant until death, whereas available information on the efficacy of ReSTOR and other multifocal IOLs does not cover many years; [39] [40] [41] [42] (3) the external validity of our spectacle cost survey could be challenged as ophthalmologists were not selected at random, but the cost structure was consistent with national statistics; 33 (4) we fully costed savings from avoided refraction visits after ReSTOR, which may be disputed as refraction could be a marginal reason for ophthalmic visits. However, avoided visits were not a major component of ReSTOR savings.
Our model, applying to the Netherlands, showed that savings from ReSTOR implants mainly benefited society, that is, patients. The explanation is simply that multifocal IOL costs were excluded from the NHS budget, which paid for cataract surgery and monofocal IOLs only, but not the costs of subsequent refraction visits and spectacles; patients avoided costs relating to professional care and refraction only. It is worth noting that costs met by patients, including the supplementary multifocal IOL payment, exceeded those of the NHS. Hence, provided the procedure has been judged as effective and safe, our results support the argument that patients should be wholly free to control their own budget for refraction correction during cataract surgery, according to their financial circumstances, and without any economic control from the Dutch NHS. Any NHS that would deny them this right may be regarded as economically irrational and unfairly interventionist.
In conclusion, according to our data and model, ReSTOR was always a cost-saving alternative to monofocal IOLs implanted during cataract surgery, when viewed from both society and NHS perspectives. Various sensitivity analyses confirmed the robustness of our findings.
